Search

Your search keyword '"Störk, S."' showing total 638 results
Start Over Author "Störk, S."
638 results on '"Störk, S."'

2. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP)

Author

Horn, A., Krist, L., Lieb, W., Montellano, F. A., Kohls, M., Haas, K., Gelbrich, G., Bolay-Gehrig, S. J., Morbach, C., Reese, J. P., Störk, S., Fricke, J., Zoller, T., Schmidt, S., Triller, P., Kretzler, L., Rönnefarth, M., Von Kalle, C., Willich, S. N., Kurth, F., Steinbeis, F., Witzenrath, M., Bahmer, T., Hermes, A., Krawczak, M., Reinke, L., Maetzler, C., Franzenburg, J., Enderle, J., Flinspach, A., Vehreschild, J., Schons, M., Illig, T., Anton, G., Ungethüm, K., Finkenberg, B. C., Gehrig, M. T., Savaskan, N., Heuschmann, P. U., Keil, T., and Schreiber, S.

Published
2021
Full Text
View/download PDF

3. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

Author

De Backer, G., Jankowski, P., Kotseva, K., Mirrakhimov, E., Reiner, Z., Rydén, L., Tokgözoğlu, L., Wood, D., De Bacquer, D., Abreu, A., Aguiar, C., Badariene, J., Bruthans, J., Castro Conde, A., Cifkova, R., Crowley, J., Davletov, K., Bacquer, D. De, De Smedt, D., De Sutter, J., Deckers, J.W., Dilic, M., Dolzhenko, M., Druais, H., Dzerve, V., Erglis, A., Fras, Z., Gaita, D., Gotcheva, N., Grobbee, D.E., Gyberg, V., Hasan Ali, H., Heuschmann, P., Hoes, A.W., Lalic, N., Lehto, S., Lovic, D., Maggioni, A.P., Mancas, S., Marques-Vidal, P., Mellbin, L., Miličić, D., Oganov, R., Pogosova, N., Reiner, Ž., Stagmo, M., Störk, S., Sundvall, J., Tsioufis, K., Vulic, D., Wood, D.A., Jennings, C., Adamska, A., Adamska, S., Tuomilehto, J., Schnell, O., Fiorucci, E., Glemot, M., Larras, F., Missiamenou, V., Maggioni, A., Taylor, C., Ferreira, T., Lemaitre, K., Raman, L., DeSmedt, D., Willems, A.M., De Pauw, M., Vervaet, P., Bollen, J., Dekimpe, E., Mommen, N., Van Genechten, G., Dendale, P., Bouvier, C.A., Chenu, P., Huyberechts, D., Persu, A., Begic, A., Durak Nalbantic, A., Dzubur, A., Hadzibegic, N., Iglica, A., Kapidjic, S., Osmanagic Bico, A., Resic, N., Sabanovic Bajramovic, N., Zvizdic, F., Kovacevic-Preradovic, T., Popovic-Pejicic, S., Djekic, D., Gnjatic, T., Knezevic, T., Kos, Lj, Stanetic, B., Topic, G., Georgiev, Borislav, Terziev, A., Vladimirov, G., Angelov, A., Kanazirev, B., Nikolaeva, S., Tonkova, D., Vetkova, M., Milicic, D., Bosnic, A., Dubravcic, M., Glavina, M., Mance, M., Pavasovic, S., Samardzic, J., Batinic, T., Crljenko, K., Delic-Brkljacic, D., Dula, K., Golubic, K., Klobucar, I., Kordic, K., Kos, N., Nedic, M., Olujic, D., Sedinic, V., Blazevic, T., Pasalic, A., Percic, M., Sikic, J., Cífková, R., Hašplová, K., Šulc, P., Wohlfahrt, P., Mayer, O., Jr., Cvíčela, M., Filipovský, J., Gelžinský, J., Hronová, M., Hasan-Ali, H., Bakery, S., Mosad, E., Hamed, H.B., Ibrahim, A., Elsharef, M.A., Kholef, E.F., Shehata, A., Youssef, M., Elhefny, E., Farid, H., Moustafa, T.M., Sobieh, M.S., Kabil, H., Abdelmordy, A., Kiljander, E., Kiljander, P., Koukkunen, H., Mustonen, J., Cremer, C., Frantz, S., Haupt, A., Hofmann, U., Ludwig, K., Melnyk, H., Noutsias, M., Karmann, W., Prondzinsky, R., Herdeg, C., Hövelborn, T., Daaboul, A., Geisler, T., Keller, T., Sauerbrunn, D., Walz-Ayed, M., Ertl, G., Leyh, R., Ehlert, T., Klocke, B., Krapp, J., Ludwig, T., Käs, J., Starke, C., Ungethüm, K., Wagner, M., Wiedmann, S., Tolis, P., Vogiatzi, G., Sanidas, E., Tsakalis, K., Kanakakis, J., Koutsoukis, A., Vasileiadis, K., Zarifis, J., Karvounis, C., Gibson, I., Houlihan, A., Kelly, C., O'Donnell, M., Bennati, M., Cosmi, F., Mariottoni, B., Morganti, M., Cherubini, A., Di Lenarda, A., Radini, D., Ramani, F., Francese, M.G., Gulizia, M.M., Pericone, D., Aigerim, K., Zholdin, B., Amirov, B., Assembekov, B., Chernokurova, E., Ibragimova, F., Kodasbayev, A., Markova, A., Asanbaev, A., Toktomamatov, U., Tursunbaev, M., Zakirov, U., Abilova, S., Arapova, R., Bektasheva, E., Esenbekova, J., Neronova, K., Baigaziev, K., Baitova, G., Zheenbekov, T., Andrejeva, T., Bajare, I., Kucika, G., Labuce, A., Putane, L., Stabulniece, M., Klavins, E., Sime, I., Gedvilaite, L., Pečiuraite, D., Sileikienė, V., Skiauteryte, E., Solovjova, S., Sidabraite, R., Briedis, K., Ceponiene, I., Jurenas, M., Kersulis, J., Martinkute, G., Vaitiekiene, A., Vasiljevaite, K., Veisaite, R., Plisienė, J., Šiurkaitė, V., Vaičiulis, Ž., Czarnecka, D., Kozieł, P., Podolec, P., Nessler, J., Gomuła, P., Mirek-Bryniarska, E., Bogacki, P., Wiśniewski, A., Pająk, A., Wolfshaut-Wolak, R., Bućko, J., Kamiński, K., Łapińska, M., Paniczko, M., Raczkowski, A., Sawicka, E., Stachurska, Z., Szpakowicz, M., Musiał, W., Dobrzycki, S., Bychowski, J., Kosior, D.A., Krzykwa, A., Setny, M., Rak, A., Gąsior, Z., Haberka, M., Szostak-Janiak, K., Finik, M., Liszka, J., Botelho, A., Cachulo, M., Sousa, J., Pais, A., Durazzo, A., Matos, D., Gouveia, R., Rodrigues, G., Strong, C., Guerreiro, R., Aguiar, J., Cruz, M., Daniel, P., Morais, L., Moreira, R., Rosa, S., Rodrigues, I., Selas, M., Apostu, A., Cosor, O., Gaita, L., Giurgiu, L., Hudrea, C., Maximov, D., Moldovan, B., Mosteoru, S., Pleava, R., Ionescu, M., Parepa, I., Arutyunov, A., Ausheva, A., Isakova, S., Karpova, A., Salbieva, A., Sokolova, O., Vasilevsky, A., Pozdnyakov, Y., Antropova, O., Borisova, L., Osipova, I., Aleksic, M., Crnokrak, B., Djokic, J., Hinic, S., Vukasin, T., Zdravkovic, M., Lalic, N.M., Jotic, A., Lalic, K., Lukic, L., Milicic, T., Macesic, M., Stanarcic Gajovic, J., Stoiljkovic, M., Djordjevic, D., Kostic, S., Tasic, I., Vukovic, A., Jug, B., Juhant, A., Krt, A., Kugonjič, U., Chipayo Gonzales, D., Gómez Barrado, J.J., Kounka, Z., Marcos Gómez, G., Mogollón Jiménez, M.V., Ortiz Cortés, C., Perez Espejo, P., Porras Ramos, Y., Colman, R., Delgado, J., Otero, E., Pérez, A., Fernández-Olmo, M.R., Torres-LLergo, J., Vasco, C., Barreñada, E., Botas, J., Campuzano, R., González, Y., Rodrigo, M., de Pablo, C., Velasco, E., Hernández, S., Lozano, C., González, P., Castro, A., Dalmau, R., Hernández, D., Irazusta, F.J., Vélez, A., Vindel, C., Gómez-Doblas, J.J., García Ruíz, V., Gómez, L., Gómez García, M, Jiménez-Navarro, M., Molina Ramos, A., Marzal, D., Martínez, G., Lavado, R., Vidal, A., Boström-Nilsson, V., Kjellström, B., Shahim, B., Smetana, S., Hansen, O., Stensgaard-Nake, E., Klijn, A.J., Mangus, T.J.P., Peters, R.J.G., Scholte op Reimer, W., Snaterse, M., Aydoğdu, S., Ç Erol, Otürk, S., Tulunay Kaya, C., Ahmetoğlu, Y., Ergene, O., Akdeniz, B., Çırgamış, D., Akkoyun H Kültürsay, S., Kayıkçıoğlu, M., Çatakoğlu, A.B., Çengel, A., Koçak, A.A., Ağırbaşlı, M.A., Açıksarı, G., Çekin, M.E., Kaya, E.B., Koçyiğit, D., Öngen, Z., Özmen, E., Sansoy, V., Kaya, A., Oktay, V., Temizhan, A., Ünal, S., İ Yakut, Kalkan, A.K., Bozkurt, E., Kasapkara, H.A., Faradzh, C., Hrubyak, L., Konoplianyk, L., Kozhuharyova, N., Lobach, L., Nesukai, V., Nudchenko, O., Simagina, T., Yakovenko, L., Azarenko, V., Potabashny, V., Bazylevych, A., Bazylevych, M., Kaminska, K., Panchenko, L., Shershnyova, O., Ovrakh, T., Serik, S., Kolesnik, T., Kosova, H., Hoye P Atkin, A., Fellowes, D., Lindsay, S., Atkinson, C., Kranilla, C., Vinod, M., Beerachee, Y., Bennett, C., Broome, M., Bwalya, A., Caygill, Lindsay, Dinning, L., Gillespie, A., Goodfellow, R., Guy, J., Idress, T., Mills, C., Morgan, C., Oustance, N., Singh, N., Yare, M., Jagoda, J.M., Bowyer, H., Christenssen, V., Groves, A., Jan, A., Riaz, A., Gill, M., Sewell, T.A., Gorog, D., Baker, M., De Sousa, P., Mazenenga, T., Porter, J., Haines, F., Peachey, T., Taaffe, J., Wells, K., Ripley, D.P., Forward, H., McKie, H., Pick, S.L., Thomas, H.E., Batin, P.D., Exley, D., Rank, T., Wright, J., Kardos, A., Sutherland, S.-B., Wren, L., Leeson, P., Barker, D., Moreby, B., Sawyer, J., Stirrup, J., Brunton, M., Brodison, A., Craig, J., Peters, S., Kaprielian, R., Bucaj, A., Mahay, K., Oblak, M., Gale, C., Pye, M., McGill, Y., Redfearn, H., Fearnley, M., De Backer, Guy, Jankowski, Piotr, Kotseva, Kornelia, Mirrakhimov, Erkin, Reiner, Željko, Rydén, Lars, Tokgözoğlu, Lale, Wood, David, and De Bacquer, Dirk

Published
2019
Full Text
View/download PDF

4. HO-1 concentrations 24 hours after cardiac surgery are associated with the incidence of acute kidney injury: a prospective cohort study

Author

Magyar A, Wagner M, Thomas P, Malsch C, Schneider R, Störk S, Heuschmann PU, Leyh RG, and Oezkur M

Subjects
acute kidney injury, cardiac surgery, heme oxygenase-1, cardiopulmonary bypass, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Attila Magyar,1,2 Martin Wagner,2–4 Phillip Thomas,1,2 Carolin Malsch,2 Reinhard Schneider,3 Stefan Störk,4,5 Peter U Heuschmann,2,4,6 Rainer G Leyh,1 Mehmet Oezkur1,21Department of Cardiovascular Surgery, University Hospital Würzburg, Würzburg, Germany; 2Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany; 3Division of Nephrology, Department of Medicine I, University Hospital Würzburg, Würzburg, Germany; 4Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany; 5Division of Cardiology, Department of Medicine I, University Hospital Würzburg, Würzburg, Germany; 6Clinical Trial Center Würzburg, University Hospital Würzburg, Würzburg, Germany Background: Acute kidney injury (AKI) is a serious complication after cardiac surgery that is associated with increased mortality and morbidity. Heme oxygenase-1 (HO-1) is an enzyme synthesized in renal tubular cells as one of the most intense responses to oxidant stress linked with protective, anti-inflammatory properties. Yet, it is unknown if serum HO-1 induction following cardiac surgical procedure involving cardiopulmonary bypass (CPB) is associated with incidence and severity of AKI. Patients and methods: In the present study, we used data from a prospective cohort study of 150 adult cardiac surgical patients. HO-1 measurements were performed before, immediately after and 24 hours post-CPB. In univariate and multivariate analyses, the association between HO-1 and AKI was investigated. Results: AKI with an incidence of 23.3% (35 patients) was not associated with an early elevation of HO-1 after CPB in all patients (P=0.88), whereas patients suffering from AKI developed a second burst of HO-1 24 hours after CBP. In patients without AKI, the HO-1 concentrations dropped to baseline values (P=0.031). Furthermore, early HO-1 induction was associated with CPB time (P=0.046), while the ones 24 hours later lost this association (P=0.219). Conclusion: The association of the second HO-1 burst 24 hours after CBP might help to distinguish between the causality of AKI in patients undergoing CBP, thus helping to adapt patient stratification and management. Keywords: acute kidney injury, cardiac surgery, heme oxygenase-1, cardiopulmonary bypass

Published
2019

7. Grundlegende Strukturmerkmale eines kardiologischen Telemedizinzentrums für Patienten mit Herzinsuffizienz und implantierten Devices, Herzrhythmusstörungen und erhöhtem Risiko für den plötzlichen Herztod: Empfehlungen der Arbeitsgruppe 33 Telemonitoring in der Deutschen Gesellschaft für Kardiologie, Herz- und Kreislaufforschung e. V.

Author

Helms, T. M., Stockburger, M., Köhler, F., Leonhardt, V., Müller, A., Rybak, K., Sack, S., Schwab, J. O., Störk, S., Zippel-Schultz, B., and Perings, C. A.

Published
2019
Full Text
View/download PDF

10. Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis.

Author

Kerwagen, F, Riemer, U, Wachter, R, von Haehling, S, Abdin, A, Böhm, M, Schulz, M, Störk, S, Kerwagen, F, Riemer, U, Wachter, R, von Haehling, S, Abdin, A, Böhm, M, Schulz, M, and Störk, S

Abstract

BACKGROUND: Guideline-directed medical therapy (GDMT) is the cornerstone in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) and novel substances such as sacubitril/valsartan (S/V) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated marked clinical benefits. We investigated their implementation into real-world HF care in Germany before, during, and after the COVID-19 pandemic period. METHODS: The IQVIA LRx data set is based on ∼80% of 73 million people covered by the German statutory health insurance. Prescriptions of S/V were used as a proxy for HFrEF. Time trends were analysed between Q1/2016 and Q2/2023 for prescriptions for S/V alone and in combination therapy with SGLT2i. FINDINGS: The number of patients treated with S/V increased from 5260 in Q1/2016 to 351,262 in Q2/2023. The share of patients with combination therapy grew from 0.6% (29 of 5260) to 14.2% (31,128 of 219,762) in Q2/2021, and then showed a steep surge up to 54.8% (192,429 of 351,262) in Q2/2023, coinciding with the release of the European Society of Cardiology (ESC) guidelines for HF in Q3/2021. Women and patients aged >80 years were treated less often with combined therapy than men and younger patients. With the start of the COVID-19 pandemic, the number of patients with new S/V prescriptions dropped by 17.5% within one quarter, i.e., from 26,855 in Q1/2020 to 22,145 in Q2/2020, and returned to pre-pandemic levels only in Q1/2021. INTERPRETATION: The COVID-19 pandemic was associated with a 12-month deceleration of S/V uptake in Germany. Following the release of the ESC HF guidelines, the combined prescription of S/V and SGLT2i was readily adopted. Further efforts are needed to fully implement GDMT and strengthen the resilience of healthcare systems during public health crises. FUNDING: Supported by Novartis Pharma GmbH, Nuremberg, Germany.

Published
2023

12. Der Einfluss von psychosozialer Belastung auf die Prognose von Patient:innen mit Herzinsuffizienz und komorbider COPD

Author

Boczor, S, Eisele, M, Rakebrandt, A, Menzel, A, Blozik, E, Träder, JM, Störk, S, Hermann-Lingen, C, and Scherer, M

Subjects
ddc: 610, Medicine and health
Abstract

Hintergrund: Herzinsuffizienz (HI) und chronisch obstruktive Lungenkrankheit (COPD) treten häufig gemeinsam auf. Nachgewiesen ist, dass HI-Komorbidität bei COPD-Patient:innen die COPD-bedingte Hospitalisierung und Gesamtmortalität erhöht und vice versa. Auch Depression und Angsterkrankungen [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

13. Der Einfluss von psychosozialer Belastung auf die Prognose hausärztlicher Patientinnen und Patienten mit Herzinsuffizienz und komorbider Nierenerkrankung

Author

Boczor, S, Eisele, M, Rakebrandt, A, Menzel, A, Blozik, E, Träder, JM, Störk, S, Hermann-Lingen, C, and Scherer, M

Subjects
ddc: 610, Medicine and health
Abstract

Hintergrund: Sowohl psychosoziale Belastung (PSB: Depression/Angsterkrankungen) als auch chronische Nierenerkrankungen (NE) erhöhen das Mortalitäts- und Hospitalisierungsrisiko bei Patient:innen mit Herzinsuffizienz (HI). Unklar ist bisher, ob PSB den bekannten Einfluss von Nierenerkrankungen [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

14. Secondary prevention in diabetic and nondiabetic coronary heart disease patients: Insights from the German subset of the hospital arm of the EUROASPIRE IV and V surveys

Author

Ungethüm, K., primary, Wiedmann, S., additional, Wagner, M., additional, Leyh, R., additional, Ertl, G., additional, Frantz, S., additional, Geisler, T., additional, Karmann, W., additional, Prondzinsky, R., additional, Herdeg, C., additional, Noutsias, M., additional, Ludwig, T., additional, Käs, J., additional, Klocke, B., additional, Krapp, J., additional, Wood, D., additional, Kotseva, K., additional, Störk, S., additional, and Heuschmann, P. U., additional

Published
2022
Full Text
View/download PDF

15. Severity score-based study of predictors and clinical correlates of Post-COVID Syndrome (PCS) in Germany

Author

Bahmer, T, primary, Borzikowsky, C, additional, Lieb, W, additional, Horn, A, additional, Krist, L, additional, Fricke, J, additional, Scheibenbogen, C, additional, Rabe, K F, additional, Maetzler, W, additional, Maetzler, C, additional, Laudien, M, additional, Frank, D, additional, Ballhausen, S, additional, Viebke, A, additional, Hermes, A, additional, Muljukov, O, additional, Haeusler, K G, additional, El Mokhtari, N E, additional, Witzenrath, M, additional, Zoller, T, additional, Vehreschild, J J, additional, Hopff, S, additional, Anton, G, additional, Krefting, D, additional, Reinke, L, additional, Hein, G, additional, Montellano, F A, additional, Kohls, M, additional, Morbach, C, additional, Störk, S, additional, Reese, J, additional, Keil, T, additional, Heuschmann, P, additional, Krawczak, M, additional, and Schreiber, S, additional

Published
2022
Full Text
View/download PDF

16. Aufbau und Organisation von Herzinsuffizienz-Netzwerken (HF‑NETs) und Herzinsuffizienz-Einheiten („Heart Failure Units“, HFUs) zur Optimierung der Behandlung der akuten und chronischen Herzinsuffizienz: Gemeinsame Empfehlungen der DGK und der DGTHG zur Behandlung der Herzinsuffizienz

Author

Ertl, G., Angermann, C. E., Bekeredjian, R., Beyersdorf, F., Güder, G., Gummert, J., Katus, H. A., Kindermann, I., Pauschinger, M., Perings, S., Raake, P. W. J., Störk, S., Scheidt, W. von, Welz, S., and Böhm, M.

Published
2016
Full Text
View/download PDF

18. Morbus Fabry

Author

Weidemann, F., Störk, S., Sommer, C., Üçeyler, N., Ertl, G., Wanner, C., and Krämer, J.

Published
2015
Full Text
View/download PDF

21. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology

Author

Gyberg, Viveca, De Bacquer, Dirk, Kotseva, Kornelia, De Backer, Guy, Schnell, Oliver, Sundvall, Jouko, Tuomilehto, Jaakko, Wood, David, Rydén, Lars, Kotseva, K., De Backer, G., Amouyel, P., Bruthans, J., Castro Conde, A., Cifkova, R., De Bacquer, D., De Sutter, J., Deckers, J.W., Dilic, M., Dolzhenko, M., Erglis, A., Ferreira, T., Fraz, Z., Gaita, D., Gielen, S., Gotcheva, N., Goudevenos, I., Gyberg, V., Heuschmann, P., Laucevicius, A., Lehto, S., Lovic, D., Manini, M., Maggioni, A.P., Miličić, D., Moore, D., Nicolaides, E., Pajak, A., Pogosova, N., Reiner, Ž., Rydén, L., Schnell, O., Stagmo, M., Störk, S., Sundvall, J., Tokgözoğlu, L., Tuomilehto, J., Vulic, D., Wood, D., Wood, D.A., Kotseva, K., Jennings, C., Adamska, A., Rydén, L., Gyberg, V., Tuomilehto, J., Schnell, O., Manini, M., Ferreira, T., Taylor, C., Konte, M., Glemot, M., De Bacquer, D., De Backer, G., Sundvall, J., Lund, L., Leiviskä, J., De Bacquer, D., De Backer, G., De Pauw, M., Ghysbrecht, C., Vervaet, P., Maria Middelares, A.Z., De Sutter, J., Pardaens, S., Willems, A.M., Sint Lucas, A.Z., Cambier, P., Claeys, R., Deweerdt, N., Nimmegeers, J., Vandekerckhove, H., Verloove, H., Versee, L., Vulic, D., Djekic, D., Malesevic, G., Pejicic, S., Srdic, S., Dilic, M., Begic, A., Hodzic, E., Kulic, M., Sabanovic-Bajramovic, N., Tahirovic, E., Iveljic, I., Kovcic, J., Kusljugic, Z., Nurkic, M., Gotcheva, N., Baycheva, V., Georgiev, B., Vladimirov, G., Gotchev, D., Ivanov, S., Miličić, D., Samardžić, J., Perić, B., Sičaja, M., Nicolaides, E., Eftychiou, C., Eteocleous, N., Georgiou, P., Hadjilouca, C., Moutiris, J.A., Nicolaou, R., Papadopoulos, K., Patsalou, M., Bruthans, J., Cífková, R., Krajcoviechova, A., Wohlfahrt, P., Filipovský, J., Krizek, M., Kviderova, Z., Mayer, O., Vágovičová, P., Vanek, J., Seidlerova, J., Timoracká, K., Adamkova, V., Belohoubek, J., Galovcova, M., Zelenkova, V., Lehto, S., Kiljander, E., Kiljander, P., Kylmaoja, P., Lehto, H.R., Olkkonen, S., Pennanen, J., Herranen, M., Amouyel, P., Astolfi, A.L., Balik, S., Beauchant, S., Dallongeville, J., Devoghelaere, C., Fievet, N., Garboni, P., Lemaire, B., Marecaux, N., Montaye, M., Karmann, W., Held, S., Heuschmann, P., Eichstädt, K., Deckert, L., Fischer, D., Gerhardt, A., Kircher, J., Memmel, Y., Nolte, K., Schich, M., Wahl, V., Wagner, M., Störk, S., Ertl, G., Güntner, S., Leyh, R., Goudevenos, I., Kalantzi, K., Athanassias, D., Goumas, G., Krimbas, P., Richter, D., Sakellariou, D., Agrios, J., Matthaios, I., Papadopoulou, E., Toumanidis, S., Tsouna-Hatjis, E., Boufidou, A., Makedou, K., Lilis, L., Moore, D., Broderick, G., Fallon, N., Storey, S., Baronenko, I., Dormidontova, G., Dulkevica, A., Dzerve, V., Erglis, A., Andrejeva, T., Bricina, N., Jakovleva, J., Jaunromane, A., Keive, E., Klovane, M., Lurina, D., Makarova, L., Matisone, D., Mintale, I., Pahomova-Strautina, E., Putane, L., Stabulniece, M., Vasiljevs, D., Vevere, G., Vilks, J., Laucevicius, A., Alitoit, I., Badariene, J., Grabliauskaite, I., Jursyte, I., Paleviciute, E., Petrulioniene, Z., Serpytis, P., Serpytis, R., Solovjova, S., Smagriunaite, V., Babarskiene, R., Ceponiene, I., Gustiene, O., Karaliute, R., Rumbinaite, E., Slapikas, R., Smalinskas, V., Verseckaite, R., Pająk, A., Brzezicka, E., Łysek, R., Misiowiec, W., Wolfshaut-Wolak, R., Nessler, J., Podolec, P., Mirek-Bryniarska, E., Grodecki, J., Czarnecka, D., Łukaszewska, A., Jankowski, P., Bogacki, P., Gaita, D., Avram, C., Barzuca, E., Gaita, L., Jurca-Simina, F., Iancu, O.C., Lazar, A., Iurciuc, M., Iurciuc, S., Mal, M., Mancas, S., Mihaescu, A., Mociar, D., Mosteoru, S., Pescariu, S., Petrescu, L., Sasec, C., Schiller, A., Amarie, L., Andronic, A., Calin, S., Ciobanu, A., Cotoban, A., Guberna, S., Lungeanu, L., Mihalcea, D., Niculescu, N., Rimbas, R., Udroiu, C., Vinereanu, D., Pogosova, N., Ausheva, A., Boytsov, S., Kursakov, A., Oganov, R., Pozdnyakov, Y., Skazin, N., Lovic, D., Lovic, B., Nedeljkovic, M., Ostojic, M., Djordjevic, D., Kostic, S., Tasic, I., Zdravkovic, M., Anđić, M., Filipović, T., Ilić-Stojanović, O., Ješić-Jukić, M., Jevsnik, N., Lazović, M., Radović, A., Radović, D., Rosić, D., Spiroski, D., Stevović, S., Vidaković, T., Vuković-Dejanović, V., Fras, Z., Jug, B., Juhant, A., Poljancic, A., Poljancic, L., Castro Conde, A., Dalmau Gonzalez-Gallarza, R., Iniesta Manjavacas, A.M., Stagmo, M., Jernhed, H., Stensgaard, E., Gyberg, V., Boström, V., Edman Jönsson, C., Hage, C., Deckers, J.W., Khatibi, S., Yongzhao, F., Veerhoek, M., Smits, P.C., Minneboo, M., Peters, R.J.G., Scholte op Reimer, W., Snaterse-Zuidam, M., Tokgözoğlu, L., Asil, S., Kaya, B., Koçyiğit, D., Kozluca, V., Tulunay Kaya, C., Akyldz, İ., Ergene, O., Varş, E., Akdeniz, B., Göldeli, Ö., Kozan, Ö., Özpelit, E., Altay, S., Çam, N., Eren, M., Kaykçoğlu, M., Kültürsay, H., Aytekin, V., Burak Çatakoğlu, A., Abac, A., Candemir, M., Ünlü, S., Oğuz, A., Barçn, C., Yaşar, S., Yokuşoğlu, M., Aydoğdu, S., Temizhan, A., Ünal, S., Altuğ Çakmak, H., Çimci, M., Öngen, Z., Ateş, G., Koylan, N., Emet, S., Umman, B., Bostan, C., Sansoy, V., Kemal Erol, M., Kemal Kalkan, A., Kaymaz, C., Poçi, N., Dolzhenko, M., Getman, T., Konoplyanik, L., Klimenko, L., Lobach, L., Luchinskaya, Y., Lurie, L., Lutay, M., Mitchenko, E., Nemchena, O., Nosenko, N., Perepelchenko, N., Potashev, S., Radchenko, A., Romanov, V., Shumakov, V., Simagina, T., Sirenko, Y., Sychov, O., Mohnacheva, N., Verezhnikova, A., Zharinov, O., Lishnevskaya, V., Mikropulo, I., Prihodko, V., Shapovalenko, I., Wood, D., Adamska, A., Evans, J., Ioannides, K., Jennings, C., Kasonta, A., Kotseva, K., Onyango, H., Rapacz, A., Wrotniak, B., Dubrey, S., Barbir, M., Connolly, S., Dancy, M., Collins, P., and Kaprielian, R.

Published
2015
Full Text
View/download PDF

22. Wirkt sich hausärztliches Wissen um Depression/Ängste auf die Prognose von Patientinnen und Patienten mit Herzinsuffizienz aus? Ergebnisse der RECODE-HF-Studie

Author

Eisele, M, Boczor, S, Rakebrandt, A, Blozik, E, Träder, JM, Störk, S, Herrmann-Lingen, C, and Scherer, M

Subjects
ddc: 610, Medicine and health
Abstract

Hintergrund: Psychosoziale Faktoren sind bei Herzinsuffizienzpatient:innen mit erhöhter Hospitalisierung und Mortalität assoziiert. Ziel dieser Untersuchung ist zu prüfen, ob die Erkennung psychischer Belastungen und nachfolgende Unterstützung/Behandlung die Prognose verbessern. [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2021
Full Text
View/download PDF

27. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Author

Abraham, W.T. Lindenfeld, J. Ponikowski, P. Agostoni, P. Butler, J. Desai, A.S. Filippatos, G. Gniot, J. Fu, M. Gullestad, L. Howlett, J.G. Nicholls, S.J. Redon, J. Schenkenberger, I. Silva-Cardoso, J. Störk, S. Krzysztof Wranicz, J. Savarese, G. Brueckmann, M. Jamal, W. Nordaby, M. Peil, B. Ritter, I. Ustyugova, A. Zeller, C. Salsali, A. Anker, S.D.

Abstract

Aims: The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). Methods and results: HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (>40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The primary endpoint was 6-minute walk test distance (6MWTD) change to Week 12. Key secondary endpoints included Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) and Chronic Heart Failure Questionnaire Self-Administered Standardized format (CHQ-SAS) dyspnoea score. 6MWTD median (95% confidence interval) differences, empagliflozin vs. placebo, at Week 12 were-4.0 m (-16.0, 6.0; P = 0.42) and 4.0 m (-5.0, 13.0; P = 0.37) in EMPERIAL-Reduced and EMPERIAL-Preserved, respectively. As the primary endpoint was non-significant, all secondary endpoints were considered exploratory. Changes in KCCQ-TSS and CHQ-SAS dyspnoea score were non-significant. Improvements with empagliflozin in exploratory pre-specified analyses of KCCQ-TSS responder rates, congestion score, and diuretic use in EMPERIAL-Reduced are hypothesis generating. Empagliflozin adverse events were consistent with those previously reported. Conclusion: The primary outcome for both trials was neutral. Empagliflozin was well tolerated in HF patients, with and without T2D, with a safety profile consistent with that previously reported in T2D. Hypothesis-generating improvements in exploratory analyses of secondary endpoints with empagliflozin in HFrEF were observed. © 2020 Published on behalf of the European Society of Cardiology. All rights reserved.

Published
2021

35. Zusammenhang zwischen psychischer Belastung und Adhärenz bei Patienten mit Herzinsuffizienz

Author

Eisele, M, Harder, M, Rakebrandt, A, Boczor, S, Marx, G, Blozik, E, Träder, JM, Störk, S, Herrmann-Lingen, C, and Scherer, M

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Hintergrund und Stand (inter)nationaler Forschung: Herzinsuffizienz ist eine Erkrankung, mit schlechter Prognose. Psychische Belastungen treten häufig zusätzlich auf und können die Prognose verschlechtern. Eine mögliche Ursache könnte eine durch psychische Belastung verschlechterte[zum vollständigen Text gelangen Sie über die oben angegebene URL], 19. Deutscher Kongress für Versorgungsforschung (DKVF)

Published
2020
Full Text
View/download PDF

36. Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document

Author

Seferović, P.M. Piepoli, M.F. Lopatin, Y. Jankowska, E. Polovina, M. Anguita-Sanchez, M. Störk, S. Lainščak, M. Miličić, D. Milinković, I. Filippatos, G. Coats, A.J.S. in collaboration with the Heart Failure Association Board of the European Society of Cardiology

Abstract

Heart failure (HF) is the major contributor to cardiovascular morbidity and mortality. Given its rising prevalence, the costs of HF care can be expected to increase. Multidisciplinary management of HF can improve quality of care and survival. However, specialized HF programmes are not widely available in most European countries. These circumstances underlie the suggestion of the Heart Failure Association (HFA). of the European Society of Cardiology (ESC) for the development of quality of care centres (QCCs). These are defined as health care institutions that provide multidisciplinary HF management at all levels of care (primary, secondary and tertiary), are accredited by the HFA/ESC and are implemented into existing health care systems. Their major goals are to unify and improve the quality of HF care, and to promote collaboration in education and research activities. Three types of QCC are suggested: community QCCs (primary care facilities able to provide non-invasive assessment and optimal therapy); specialized QCCs (district hospitals with intensive care units, able to provide cardiac catheterization and device implantation services), and advanced QCCs (national reference centres able to deliver advanced and innovative HF care and research). QCC accreditation will require compliance with general and specific HFA/ESC accreditation standards. General requirements include confirmation of the centre's existence, commitment to QCC implementation, and collaboration with other QCCs. Specific requirements include validation of the centre's level of care, service portfolio, facilities and equipment, management, human resources, process measures, quality indicators and outcome measures. Audit and recertification at 4–6-year intervals are also required. The implementation of QCCs will evolve gradually, following a pilot phase in selected countries. The present document summarizes the definition, major goals, development, classification and crucial aspects of the accreditation process of the HFA/ESC QCC Programme. © 2020 European Society of Cardiology

Published
2020

38. A Self-administered Version of the Functioning Assessment Short Test for Use in Population-based Studies: A Pilot Study.

Author

Riegler, C, Wiedmann, S, Rücker, V, Teismann, H, Berger, K, Störk, S, Vieta, E, Faller, H, Baune, BT, Heuschmann, PU, Riegler, C, Wiedmann, S, Rücker, V, Teismann, H, Berger, K, Störk, S, Vieta, E, Faller, H, Baune, BT, and Heuschmann, PU

Abstract

BACKGROUND: The Functioning Assessment Short Test (FAST) is an interviewer-administered scale assessing functional impairment originally developed for psychiatric patients. OBJECTIVES: To adapt the FAST for the general population, we developed a self-administered version of the scale and assessed its properties in a pilot study. METHODS: The original FAST scale was translated into German via forward and backward translation. Afterwards, we adjusted the scale for self-administered application and inquired participants from two ongoing studies in Germany, 'STAAB' (Würzburg) and 'BiDirect' (Münster), both recruiting subjects from the general population across a wide age range (STAAB: 30-79 years, BiDirect: 35-65 years). To assess reliability, agreement of self-assessment with proxy-assessment by partners was measured via intraclass correlation coefficient (ICC) over the FAST score. Construct validity was estimated by conducting correlations with validated scales of depression (PHQ-9), anxiety (GAD-7), and health-related quality of life (SF-12) and regression analyses using these scales besides potentially disabling comorbidities (e.g. Chronic Back Pain (CBP)). RESULTS: Participants (n=54) had a median age of 57.0 years (quartiles: 49.8, 65.3), 46.3% were female. Reliability was moderate: ICC 0.50 (95% CI 0.46-0.54). The FAST score significantly correlated with PHQ-9, GAD-7, and the mental sub-scale of SF-12. In univariable linear regression, all three scales and chronic back pain explained variance of the FAST score. In multivariable analysis, only CBP and the SF-12 remained significant predictors. CONCLUSION: The German self-administered version of the FAST yielded moderate psychometric properties in this pilot study, indicating its applicability to assess functional impairment in the general population.

Published
2020

46. Extraction of X-ray images for a large clinical study via a PACS/data warehouse integration system

Author

Kaspar, M, Liman, L, Tullius, F, Fette, G, Ertl, M, Krebs, J, Störk, S, and Puppe, F

Subjects
study support, ddc: 610, data warehouse, 610 Medical sciences, Medicine, PACS
Abstract

Introduction: Clinical data warehouses (DWHs) may be used to provide researchers with a structured and simple access to pseudonymized clinical routine data in a homogenized format. Common data domains of DWHs are patient demographics, diagnosis codes, laboratory values, procedures, disease-related groups[for full text, please go to the a.m. URL], 64. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS)

Published
2019
Full Text
View/download PDF

49. The effect of spironolactone on diastolic function in haemodialysis patients.

Author

Hauser, T., Dornberger, V., Malzahn, U., Grebe, S. J., Liu, D., Störk, S., Nauck, M., Friedrich, N., Dörr, M., Wanner, C., Krane, V., Hammer, F., Collaborating investigators (sites), Berweck, Susanne, Biggar, Patrick, Blaser, Christoph, Bochannek, Thomas, Breunig, Frank, Brunner, Michael, and Büschges-Seraphin, Beatrix

Abstract

Heart failure with preserved ejection fraction (HFpEF) is highly prevalent in patients on maintenance haemodialysis (HD) and lacks effective treatment. We investigated the effect of spironolactone on cardiac structure and function with a specific focus on diastolic function parameters. The MiREnDa trial examined the effect of 50 mg spironolactone once daily versus placebo on left ventricular mass index (LVMi) among 97 HD patients during 40 weeks of treatment. In this echocardiographic substudy, diastolic function was assessed using predefined structural and functional parameters including E/e'. Changes in the frequency of HFpEF were analysed using the comprehensive 'HFA-PEFF score'. Complete echocardiographic assessment was available in 65 individuals (59.5 ± 13.0 years, 21.5% female) with preserved left ventricular ejection fraction (LVEF > 50%). At baseline, mean E/e' was 15.2 ± 7.8 and 37 (56.9%) patients fulfilled the criteria of HFpEF according to the HFA-PEFF score. There was no significant difference in mean change of E/e' between the spironolactone group and the placebo group (+ 0.93 ± 5.39 vs. + 1.52 ± 5.94, p = 0.68) or in mean change of left atrial volume index (LAVi) (1.9 ± 12.3 ml/m2 vs. 1.7 ± 14.1 ml/m2, p = 0.89). Furthermore, spironolactone had no significant effect on mean change in LVMi (+ 0.8 ± 14.2 g/m2 vs. + 2.7 ± 15.9 g/m2; p = 0.72) or NT-proBNP (p = 0.96). Treatment with spironolactone did not alter HFA-PEFF score class compared with placebo (p = 0.63). Treatment with 50 mg of spironolactone for 40 weeks had no significant effect on diastolic function parameters in HD patients. The trial has been registered at clinicaltrials.gov (NCT01691053; first posted Sep. 24, 2012). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Reference model agnostic querying clinical information systems purely based on terminology codes – proposal of an ideal query language

Author

Fette, G, Kaspar, M, Liman, L, Dietrich, G, Ertl, M, Krebs, J, Störk, S, and Puppe, F

Subjects
ddc: 610, Medizinische Informatik, 610 Medical sciences, Medicine
Abstract

Introduction: Data exchange between clinical institutions is currently very limited, as most hospital information systems (HIS) possess proprietary data models and therefore transfer or comparison of data between different institutions with different data models is not possible. Ideally, all clinical[for full text, please go to the a.m. URL], 63. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results